COMPANY PROFILE // THE 014 REPORT
Biohaven Ltd.
BHVN (NYSE) · Formerly: Biohaven Research Ltd.
Assembled from 2 government sources in 4.9 s
FLAGS · DISCLOSURE · SUMMARY
Missing or hidden
No flag from the records checked. 25 of 26 lists and sources checked came back clear (panel below).
✓ SEC filings✗ LEI✗ SAM registration✗ IRS return✗ State registration✗ Website✗ Lobbying registration
No LEI, no SAM registration, no IRS return, no state registration, no website, no lobbying registration on record.
Biohaven Ltd. is an SEC-registered operating company in pharmaceutical preparations, incorporated in British Virgin Islands, based in New Haven, CT; listed as BHVN (NYSE).[source] It has filed 53 documents with the SEC in the last 12 months; the latest is a SCHEDULE 13G/A, filed 2026-11-16.[source] Its largest institutional holders on 13F filings are BlackRock, Inc., MONTANOVA CAPITAL, LLC, STIFEL FINANCIAL CORP (as of 2026-06-30).[source] 25 of 26 lists and sources checked came back clear; the rest are listed with their result.[source]
- red0
- amber0
- info0
- BlackRock, Inc.$196.6M
- MONTANOVA CAPITAL, LLC$153.1M
- STIFEL FINANCIAL CORP$147.9M
- Jupiter Topco LLC$127.9M
- Woodline Partners LP$114.0M
- STATE STREET CORP$103.4M
- INFINITUM ASSET MANAGEMENT, LLC$93.0M
- D. E. Shaw & Co., Inc.$62.4M
RECORD · WEB
Ask about this entity
Answers come from this 014 first; every line is marked RECORD (our record, linked) or WEB (a web page, credited and linked).
PEOPLE · COUNSEL · LINKS
Leadership, advisers and links
Officers and directors (Forms 3, 4, 5)
- Buten Matthew · Chief Financial Officer (Officer) · latest Form 4 2026-03-03 · filing · LinkedIn search
- Car Bruce · Chief Scientific Officer (Officer) · latest Form 4 2026-03-03 · filing · LinkedIn search
- Clark George C. · VP, Chief Accounting Officer (Officer) · latest Form 4 2026-03-03 · filing · LinkedIn search
- Coric Vlad · Chief Executive Officer (Director,Officer) · latest Form 4 2026-03-03 · filing · LinkedIn search
- Gentile Kimberly · SVP, Clinical Operations (Officer) · latest Form 4 2026-03-03 · filing · LinkedIn search
- Antonijevic Irina · Director · latest Form 4 2025-05-07 · filing · LinkedIn search
- Bailey Gregory · Director · latest Form 4 2025-11-17 · filing · LinkedIn search
- CHILDS JOHN W · Director · latest Form 4/A 2026-03-09 · filing · LinkedIn search
- GREGORY JULIA P · Director · latest Form 4 2025-05-07 · filing · LinkedIn search
- HUGIN ROBERT J · Director · latest Form 4 2025-05-07 · filing · LinkedIn search
- Heffernan Michael Thomas · Director · latest Form 4 2025-05-07 · filing · LinkedIn search
- Mehta Kishan · Director · latest Form 4 2026-03-19 · filing · LinkedIn search
As reported to the SEC by the insiders themselves; SEC insider transactions data sets (Forms 3, 4, 5): 2026q1, 2025q4, 2025q3, 2025q2.
EVERY LIST AND SOURCE · DATED
Checked and clear
26 lists and sources checked: 25 CLEAR, 1 POSSIBLE MATCH, 0 MATCH. Screening lists are checked when this 014 is built; the enforcement and registry sources at the last company-engine build. Each date is the date of that check.
EVERY IDENTIFIER · LINKED
ID crosswalk
| Identifier | Value | Record |
|---|---|---|
| SEC CIK | 0001935979 | source |
| EIN | 00-0000000 | source |
| Business address (SEC) | 215 CHURCH STREET, NEW HAVEN, CT, 06510 | source |
Does not exist in the records we hold: LEI, UEI, NY DOS ID, FDIC certificate.
EACH FEEDS WATCH
Dates coming up
- 2027-03-01 · in 101 days · Next 10-K due (period ended 2026-12-31; Large accelerated filer) (computed from the fiscal year end and filer status)
- 2027-05-10 · in 171 days · Next 10-Q due (period ended 2027-03-31; Large accelerated filer) (computed from the fiscal year end and filer status)
PEERS BY SIC CODE
Industry context
SIC 2834 (pharmaceutical preparations): 568 companies in our records share this code.
federal dollars
lobbying filings
SEC filings in 12 months
flags
Peers, each with its 014
- PFIZER INC · 124 SEC filings in 12 months · $25.74B federal (possible match)
- Merck & Co., Inc. · 150 SEC filings in 12 months · $13.51B federal (possible match)
- ABBOTT LABORATORIES · 118 SEC filings in 12 months · 1 flag · $2.64B federal (possible match)
- ASTRAZENECA PLC · 140 SEC filings in 12 months · $602.8M federal (possible match)
- TEVA PHARMACEUTICAL INDUSTRIES LTD · 168 SEC filings in 12 months · $77.6M federal (possible match)
- NOVARTIS AG · 34 SEC filings in 12 months · $41.9M federal (possible match)
- Spero Therapeutics, Inc. · 41 SEC filings in 12 months · 4 flags · $39.5M federal (possible match)
- Grifols SA · 18 SEC filings in 12 months · $22.5M federal (possible match)
- SCYNEXIS INC · 54 SEC filings in 12 months · 3 flags · $18.5M federal (possible match)
- Ensysce Biosciences, Inc. · 45 SEC filings in 12 months · 3 flags · $15.1M federal (possible match)
- UNITED THERAPEUTICS Corp · 454 SEC filings in 12 months · 2 flags · $6.8M federal (possible match)
- Zoetis Inc. · 144 SEC filings in 12 months · 1 flag · $6.7M federal (possible match)
SHARED PEOPLE · SHARED ADDRESS
Network neighbours
Shared directors and officers
- Royalty Pharma plc · Coric Vlad
- Veradermics, Inc · Coric Vlad
- Serina Therapeutics, Inc. · Bailey Gregory
- Veradermics, Inc · CHILDS JOHN W
- Nurix Therapeutics, Inc. · GREGORY JULIA P
- Chubb Ltd · HUGIN ROBERT J
- Avalo Therapeutics, Inc. · Heffernan Michael Thomas
- Trevi Therapeutics, Inc. · Heffernan Michael Thomas
- enGene Therapeutics Inc. · Heffernan Michael Thomas
- Benitec Biopharma Inc. · Mehta Kishan
EVERY SOURCE · NEWEST FIRST
One timeline
- 2026-11-16 filing 8-K items 7.01,9.01 · SEC EDGAR
- 2026-10-29 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-10-29 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-10-22 filing 8-K items 7.01,9.01 · SEC EDGAR
- 2026-10-15 filing 8-K items 1.01,7.01,9.01 · SEC EDGAR
- 2026-09-10 filing 8-K items 8.01 · SEC EDGAR
- 2026-08-26 filing 8-K items 1.01,7.01,9.01 · SEC EDGAR
- 2026-08-10 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-08-10 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-08-07 officer change 8-K items 5.02,9.01 · SEC EDGAR
- 2026-07-09 officer change 8-K items 5.02,9.01 · SEC EDGAR
- 2026-05-27 filing 8-K items 7.01,9.01 · SEC EDGAR
- 2026-05-05 filing 8-K items 8.01,9.01 · SEC EDGAR
- 2026-05-04 filing 424B5 · SEC EDGAR
- 2026-05-04 filing S-3ASR · SEC EDGAR
- 2026-05-04 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-05-04 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-05-04 filing 8-K items 5.07 · SEC EDGAR
- 2026-03-13 filing DEFA14A · SEC EDGAR
- 2026-03-13 filing Proxy statement · SEC EDGAR
- 2026-03-02 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-03-02 filing S-8 · SEC EDGAR
- 2026-03-02 filing Annual report (10-K) · SEC EDGAR
- 2026-01-12 filing 8-K items 7.01,9.01 · SEC EDGAR
- 2026-01-07 filing 8-K items 8.01 · SEC EDGAR
- 2026-01-07 insider First Form 3/4/5 on record for Buten Matthew (Chief Financial Officer) · SEC Forms 3/4/5
- 2026-01-07 insider First Form 3/4/5 on record for Car Bruce (Chief Scientific Officer) · SEC Forms 3/4/5
- 2026-01-07 insider First Form 3/4/5 on record for Gentile Kimberly (SVP, Clinical Operations) · SEC Forms 3/4/5
- 2025-11-18 insider First Form 3/4/5 on record for Clark George C. (VP, Chief Accounting Officer) · SEC Forms 3/4/5
- 2025-11-17 insider First Form 3/4/5 on record for Coric Vlad (Chief Executive Officer) · SEC Forms 3/4/5
112 earlier entries
- 2025-11-13 filing 8-K items 8.01,9.01
- 2025-11-13 filing 424B5
- 2025-11-12 filing 424B5
- 2025-11-10 filing Quarterly report (10-Q)
- 2025-11-10 filing 8-K items 2.02,9.01
- 2025-08-22 filing 8-K items 7.01
- 2025-08-15 filing 8-K items 8.01,9.01
- 2025-08-15 filing 424B7
- 2025-08-11 filing Quarterly report (10-Q)
- 2025-08-11 filing 8-K items 2.02,9.01
- 2025-06-04 filing 8-K items 7.01,9.01
- 2025-05-15 filing 8-K items 7.01,9.01
- 2025-05-12 filing Quarterly report (10-Q)
- 2025-05-12 filing 8-K items 2.02,9.01
- 2025-05-07 filing 8-K items 5.07
- 2025-05-07 insider First Form 3/4/5 on record for Antonijevic Irina (Director)
- 2025-05-07 insider First Form 3/4/5 on record for Bailey Gregory (Director)
- 2025-05-07 insider First Form 3/4/5 on record for CHILDS JOHN W (Director)
- 2025-05-07 insider First Form 3/4/5 on record for GREGORY JULIA P (Director)
- 2025-05-07 insider First Form 3/4/5 on record for HUGIN ROBERT J (Director)
- 2025-05-07 insider First Form 3/4/5 on record for Heffernan Michael Thomas (Director)
- 2025-05-07 insider First Form 3/4/5 on record for Mehta Kishan (Director)
- 2025-04-28 filing 8-K items 1.01,2.03,7.01,9.01
- 2025-03-18 filing DEFA14A
- 2025-03-18 filing Proxy statement
- 2025-03-03 filing 8-K items 2.02,9.01
- 2025-03-03 filing Annual report (10-K)
- 2025-01-13 filing 8-K items 7.01,9.01
- 2024-11-12 filing 8-K items 2.02,9.01
- 2024-11-12 filing Quarterly report (10-Q)
- 2024-10-22 filing CT ORDER
- 2024-10-02 filing 8-K items 8.01,9.01
- 2024-10-01 filing 424B5
- 2024-09-30 filing 424B5
- 2024-09-23 filing 8-K items 7.01,8.01,9.01
- 2024-08-16 filing 8-K items 8.01,9.01
- 2024-08-16 filing 424B7
- 2024-08-16 filing 8-K items 8.01,9.01
- 2024-08-16 filing 424B5
- 2024-08-09 filing Quarterly report (10-Q)
- 2024-08-08 filing 8-K items 2.02,9.01
- 2024-05-17 filing 8-K items 8.01,9.01
- 2024-05-17 filing 424B7
- 2024-05-09 filing S-8
- 2024-05-09 filing 8-K items 2.02,9.01
- 2024-05-09 filing Quarterly report (10-Q)
- 2024-05-01 filing 8-K items 5.07
- 2024-04-22 filing 8-K items 8.01,9.01
- 2024-04-19 filing 424B5
- 2024-04-17 filing 424B5
- 2024-04-15 filing 8-K items 7.01,9.01
- 2024-03-18 filing DEFA14A
- 2024-03-18 filing Proxy statement
- 2024-03-12 filing 8-K items 8.01,9.01
- 2024-03-12 filing 424B7
- 2024-02-29 filing 8-K items 2.02,9.01
- 2024-02-29 filing Annual report (10-K)
- 2024-01-08 filing 8-K items 7.01,9.01
- 2023-12-29 filing 144
- 2023-11-14 filing 8-K items 2.02,9.01
- 2023-11-14 filing Quarterly report (10-Q)
- 2023-10-05 filing 8-K items 8.01,9.01
- 2023-10-04 filing 424B5
- 2023-10-03 filing 8-K items 8.01,9.01
- 2023-10-02 filing 424B5
- 2023-10-02 filing 424B5
- 2023-10-02 filing S-3ASR
- 2023-09-27 filing 8-K items 7.01,9.01
- 2023-07-31 filing Quarterly report (10-Q)
- 2023-07-31 filing 8-K items 2.02,9.01
- 2023-07-28 filing 8-K items 7.01,9.01
- 2023-05-31 filing 8-K items 7.01,9.01
- 2023-05-12 filing 8-K items 2.02,9.01
- 2023-05-12 filing S-8
- 2023-05-12 filing Quarterly report (10-Q)
- 2023-05-04 officer change 8-K items 5.02,5.07
- 2023-03-24 filing 8-K items 7.01,9.01
- 2023-03-23 filing 8-K items 2.02,9.01
- 2023-03-23 filing DEFA14A
- 2023-03-23 filing Proxy statement
- 2023-03-23 filing Annual report (10-K)
- 2023-01-10 filing 8-K items 7.01,9.01
- 2022-11-09 filing Quarterly report (10-Q)
- 2022-11-09 filing 8-K items 2.02,9.01
- 2022-10-24 filing 424B4
- 2022-10-20 filing EFFECT
- 2022-10-20 filing S-1MEF
- 2022-10-20 filing S-1/A
- 2022-10-18 filing CORRESP
- 2022-10-18 filing CORRESP
- 2022-10-18 filing Registration (S-1)
- 2022-10-18 filing UPLOAD
- 2022-10-11 filing DRS
- 2022-10-11 filing S-8
- 2022-10-03 officer change 8-K items 5.01,5.02,5.03,8.01,9.01
- 2022-09-28 filing 8-K items 7.01
- 2022-09-22 filing SEC STAFF ACTION
- 2022-09-20 filing CORRESP
- 2022-09-20 filing CERT
- 2022-09-20 filing 10-12B/A
- 2022-09-14 filing CORRESP
- 2022-09-14 filing 10-12B/A
- 2022-09-14 name change Name changed from Biohaven Research Ltd.
- 2022-09-13 filing UPLOAD
- 2022-09-07 filing 10-12B/A
- 2022-08-24 filing CORRESP
- 2022-08-24 filing 10-12B/A
- 2022-08-22 filing UPLOAD
- 2022-08-10 filing CORRESP
- 2022-08-10 filing 10-12B
- 2022-07-29 filing UPLOAD
- 2022-07-01 filing DRS
RENDERED FROM THIS PAGE
Relationship graph
Holders from 13F filings, subsidiaries from the GLEIF tree (by LEI), lobbying firms from LDA (possible match), agencies from USAspending, people from Forms 3/4/5, counsel from Exhibit 5.1, shared boards from Forms 3/4/5.
DATA MOTION // NEWEST FIRSTWhat changed
- 2026-11-16 (within 7 days) 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-10-29 (within 30 days) 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-10-29 (within 30 days) 10-Q filed
- 2026-10-22 (within 30 days) 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-10-15 (older) 8-K filed: Item 1.01 material agreement; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-09-10 (older) 8-K filed: Item 8.01 other event
- 2026-08-26 (older) 8-K filed: Item 1.01 material agreement; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-08-10 (older) 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
Dot rule: red = within 7 days, amber = within 30 days, green = older. Measured against 2026-11-20; the colour is also written out in words.
COUNTS FROM THIS PAGERelationships at a glance
PRICE · FILINGS · POSTS · NEWSMarket & news
- Price
- NYSE:BHVN The chart widget (TradingView) shows the price and the previous session's close. Seraphix publishes no price of its own.
- Open in
Open in…
Price and chart
News
Analyst estimates and earnings
Institutional holders
Short interest
Official social
Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.
- Financials
- Filed figures: published SEC values, each linked to its filing.
- Official posts
- Links to posts from the company's and agencies' verified accounts: not connected yet.
- News
- Article links (headline, date, link): not connected yet.
EVERY RESOLVED IDENTIFIER1. Identity
1 possible match held apart, matched by name only, not counted above.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| SEC CIK | 1935979 | id:sec-anchor: the SEC registrant record of this company | SEC EDGAR |
| Ticker / exchange | BHVN / NYSE | SEC company record: ticker and exchange as listed on the SEC company record | SEC EDGAR |
| CUSIP | G1110E107 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001935979 | SEC EDGAR |
possible match: matched by name only, not merged (1)
Identifiers carried by records that share the company's exact name. Not merged into the identity above.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| EPA FRS id | 110043939370 (BIOHAVEN) | name-exact: exact name match to 'Biohaven Ltd.' (no other entity shares the name) | EPA ECHO facilities |
AS FILED · EACH WITH ITS DATE AND FILING2. Filed figures
Key figures (annual filing)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Net income (loss) (fiscal year ended 2025-12-31) | -$738,822,000 | 2025-12-31 | 10-K, XBRL NetIncomeLoss | as filed | 2026-11-20 10:23 UTC | Report an error |
| Total assets (at 2025-12-31) | $451,447,000 | 2025-12-31 | 10-K, XBRL Assets | as filed | 2026-11-20 10:23 UTC | Report an error |
| Stockholders' equity (at 2025-12-31) | $52,072,000 | 2025-12-31 | 10-K, XBRL StockholdersEquity | as filed | 2026-11-20 10:23 UTC | Report an error |
| Cash and cash equivalents (at 2025-12-31) | $229,957,000 | 2025-12-31 | 10-K, XBRL CashAndCashEquivalentsAtCarryingValue | as filed | 2026-11-20 10:23 UTC | Report an error |
Company profile facts (SEC)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| SEC entity type | operating | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-20 10:23 UTC | Report an error |
| SIC industry | 2834 Pharmaceutical Preparations | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-20 10:23 UTC | Report an error |
| State of incorporation | D8 | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-20 10:23 UTC | Report an error |
| Fiscal year end (MMDD) | 1231 | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-20 10:23 UTC | Report an error |
| Business address | 215 CHURCH STREET, NEW HAVEN, CT, 06510 | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-20 10:23 UTC | Report an error |
| Exchanges | NYSE | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-20 10:23 UTC | Report an error |
Other filed values
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Operating cash flow (fiscal year ended 2025-12-31) | -$609,438,000 | 2025-12-31 | 10-K, XBRL NetCashProvidedByUsedInOperatingActivities | as filed | 2026-11-20 10:23 UTC | Report an error |
| Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31) | $715,000 | 2025-12-31 | 10-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment | as filed | 2026-11-20 10:23 UTC | Report an error |
| Operating lease liabilities (at 2025-12-31) | $45,714,000 | 2025-12-31 | 10-K, XBRL OperatingLeaseLiability | as filed | 2026-11-20 10:23 UTC | Report an error |
Latest report: 10-Q for the period ended 2026-09-30, filed 2026-10-29 · accession 0001935979-26-000092
| Item | Value | Period | Form | Filed | Accession | Retrieved | Report |
|---|---|---|---|---|---|---|---|
| Net income (loss) | -$129,279,000 | 3 months ended 2026-09-30 | 10-Q | 2026-10-29 | 0001935979-26-000092 | 2026-11-20 10:23 UTC | Report an error |
| Cash and cash equivalents | $95,754,000 | at 2026-09-30 | 10-Q | 2026-10-29 | 0001935979-26-000092 | 2026-11-20 10:23 UTC | Report an error |
Values as filed in XBRL (SEC company facts); quarterly values are the filer's own 3-month figures, never derived.
No estimates: every value is as filed and links to the filing it came from.
Registration: the SEC filer status is under "Company profile facts (SEC)" above. SAM.gov registration status: not held yet.
NEWEST FIRST · EACH LINKS TO ITS FILING3. Registration and filing timeline
- 2026-11-16 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-10-29 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-10-29 Filing 10-Q filed
- 2026-10-22 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-10-15 Filing 8-K filed: Item 1.01 material agreement; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-09-10 Filing 8-K filed: Item 8.01 other event
- 2026-08-26 Filing 8-K filed: Item 1.01 material agreement; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-08-10 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-08-10 Filing 10-Q filed
- 2026-08-07 Filing 8-K filed: Item 5.02 officer or director change; Item 9.01 exhibits
- 2026-07-09 Filing 8-K filed: Item 5.02 officer or director change; Item 9.01 exhibits
- 2026-05-27 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-05-05 Filing 8-K filed: Item 8.01 other event; Item 9.01 exhibits
- 2026-05-04 Filing 424B5 filed
- 2026-05-04 Filing S-3ASR filed
- 2026-05-04 Filing 10-Q filed
- 2026-05-04 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-05-04 Filing 8-K filed: Item 5.07 shareholder vote
- 2026-03-13 Filing DEFA14A filed
- 2026-03-13 Filing DEF 14A filed
- 2026-03-02 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-03-02 Filing S-8 filed
- 2026-03-02 Filing 10-K filed
- 2026-01-12 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-01-07 Filing 8-K filed: Item 8.01 other event
8-K item text, as filed (excerpts)
- 2026-11-16 8-K Item 7.01, Regulation FD Disclosure
Biohaven Ltd. will be making an investor presentation (the “Presentation”) at the Jefferies Global Healthcare Conference in London, United Kingdom starting today (November 16-19). A copy of the Presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K, and is incorporated herein by reference. The information in this Item 7.01, including the information set forth in Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of… the 8-K · retrieved 2026-11-20 10:23 UTC - 2026-10-29 8-K Item 2.02, Results of Operations and Financial Condition
On October 29, 2026, Biohaven Ltd. (the “Registrant”) issued a press release announcing its financial results for the third quarter ended September 30, 2026. A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report and is incorporated herein by reference. In accordance with General Instruction B.2. of Form 8-K, the information in this Item 2.02, and Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Registrant’s filings under the Securities Act… the 8-K · retrieved 2026-11-20 10:23 UTC - 2026-10-22 8-K Item 7.01, Regulation FD Disclosure
On October 22, 2026, Biohaven Ltd. (the Company) provided an update on the spinocerebeller ataxia (SCA) program. The FDA has informed Biohaven that the company’s new drug application resubmission for Vyglxia (troriluzole) in SCA has been accepted for review. The resubmission included new positive supportive analyses. The FDA communicated that it considers the resubmission a complete response to the November 4, 2025 action letter, and has assigned a user fee goal date in the first quarter of 2027. The FDA plans to convene a meeting of the Peripheral and Central Nervous System Advisory Committee to obtain input from external stakeholders. The anticipated date of the advisory committee meeting… the 8-K · retrieved 2026-11-20 10:23 UTC - 2026-10-15 8-K Item 1.01, Entry into a Material Definitive Agreement
Collaboration and License Agreement On October 8, 2026, Biohaven Ltd., together with its wholly owned subsidiaries (the “Company”), entered into a Collaboration and License Agreement (the “License Agreement”) with Ono Pharmaceutical Co., Ltd. (“Ono”). Pursuant to the License Agreement, the Company granted Ono an exclusive, royalty-bearing license, with the right to grant sublicenses subject to the terms of the License Agreement, to develop and commercialize the Company’s MoDE™ pan IgG degrader portfolio, led by BHV-1300 and including next-generation follow-on degraders BHV-1310 and BHV-1320, in Japan, South Korea, Taiwan and the countries of the Association of Southeast Asian Nations (the… the 8-K · retrieved 2026-11-20 10:23 UTC - 2026-10-15 8-K Item 7.01, Regulation FD Disclosure
On October 8, 2026, the Company issued a press release announcing the transaction contemplated by the License Agreement. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and incorporated in this Item 7.01 by reference. The information in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth… the 8-K · retrieved 2026-11-20 10:23 UTC
Each excerpt is the first part of the item's own text, copied as filed and cut at a word; the filing has the rest.
POSSIBLE MATCHES · GROUPED BY SOURCE8. Enforcement by agency
EPA ECHO facilities (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
Each record's own page holds its date and the agency document. Matched by exact name only; none of these is counted in the headline.
AS FILED · LARGEST HOLDERS10. 13F institutional holders
| Rank | Holder (13F filer) | Value held | As of | Source | Retrieved | Report |
|---|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | $196,573,505 | 2026-06-30 | SEC 13F filing | 2026-11-20 10:23 UTC | Report an error |
| 2 | MONTANOVA CAPITAL, LLC | $153,069,623 | 2026-06-30 | SEC 13F filing | 2026-11-20 10:23 UTC | Report an error |
| 3 | STIFEL FINANCIAL CORP | $147,924,530 | 2026-06-30 | SEC 13F filing | 2026-11-20 10:23 UTC | Report an error |
| 4 | Jupiter Topco LLC | $127,851,575 | 2026-06-30 | SEC 13F filing | 2026-11-20 10:23 UTC | Report an error |
| 5 | Woodline Partners LP | $113,984,966 | 2026-06-30 | SEC 13F filing | 2026-11-20 10:23 UTC | Report an error |
| 6 | STATE STREET CORP | $103,371,866 | 2026-06-30 | SEC 13F filing | 2026-11-20 10:23 UTC | Report an error |
| 7 | INFINITUM ASSET MANAGEMENT, LLC | $93,000,000 | 2026-06-30 | SEC 13F filing | 2026-11-20 10:23 UTC | Report an error |
| 8 | D. E. Shaw & Co., Inc. | $62,350,102 | 2026-06-30 | SEC 13F filing | 2026-11-20 10:23 UTC | Report an error |
| 9 | AQR CAPITAL MANAGEMENT LLC | $61,761,159 | 2026-06-30 | SEC 13F filing | 2026-11-20 10:23 UTC | Report an error |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | $49,460,273 | 2026-06-30 | SEC 13F filing | 2026-11-20 10:23 UTC | Report an error |
13F as filed: the holder's own report of its position value at the quarter end.
WHAT THIS PAGE READ
Sources
JSON · MCP · API
API and agents
The same profile as JSON: GET /company/1935979.json. The MCP server and the records API return the same data: GET /v1/record/sx:sec:0001935979. Every source URL used is listed in the file.
Get the evidence file, alerts and the API with a free key. Everything on this page stays free to read.